NCT02699723 2020-10-22
Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Stanford University
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
8 trialsNCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01835288 2018-05-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Withdrawn
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT00670150 2015-10-27
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
University of Southern California
Phase 2 Withdrawn
NCT00075413 2015-10-02
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
The University of Texas Medical Branch, Galveston
Phase 2 Withdrawn
NCT00085345 2013-07-10
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn